1. Home
  2. BIRD vs IXHL Comparison

BIRD vs IXHL Comparison

Compare BIRD & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

HOLD

Current Price

$1.06

Market Cap

30.1M

ML Signal

HOLD

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$1.87

Market Cap

35.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRD
IXHL
Founded
2015
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Apparel
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
30.1M
35.4M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
BIRD
IXHL
Price
$1.06
$1.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $18.18
AVG Volume (30 Days)
★ 382.6K
93.8K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 20.22
N/A
EPS
N/A
★ N/A
Revenue
★ $152,466,000.00
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$487.91
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.12
$0.16
52 Week High
$24.31
$6.39

Technical Indicators

Market Signals
Indicator
BIRD
IXHL
Relative Strength Index (RSI) 29.74 28.52
Support Level N/A $0.16
Resistance Level $1.46 $3.87
Average True Range (ATR) 0.17 0.21
MACD -0.00 -0.02
Stochastic Oscillator 3.91 21.89

Price Performance

Historical Comparison
BIRD
IXHL

About BIRD Allbirds Inc.

Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.

Share on Social Networks: